AREN1921

Summary

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).

To be included in AREN1921, participants must be / have

• All patients must be enrolled on APEC14B and consent to Part A – Eligibility Screening
• All patients must be < than 30 at the time of enrollment
• Patients with newly diagnosed Stage I-IV favorable histology Wilms tumor
• Patients who have an upfront nephrectomy must have at least one lymph node sampled and confirmed as a lymph node by central pathology review to be eligible
• Adequate liver and cardiac function

To be included in AREN1921, participants must not be / have

• Patient with a diagnosis of Stage V Bilateral Wilms tumor
• Patients who in the opinion of the investigator are not able to comply with the study procedures are not eligible
• Patients with any uncontrolled, intercurrent illness including but not limited to symptomatic congestive heart failure
• Patients with lung metastases as the only metastatic site who already had complete resection of all radiologically evident lung nodules, and have at least one nodule confirmed pathologically as tumor
• Prior therapy or concurrent therapy
• Pregnant and breastfeeding patients are not eligible 

Keywords

Chemotherapy; Wilms tumor